Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3593]

ASCO GU 2019: Pembrolizumab plus axitinib extended overall survival and progression-free survival versus current standard treatment for advanced kidney cancer

ASCO GU 2019: Pembrolizumab plus axitinib extended overall survival and progression-free survival versus current...

Immunotherapy can be effective in treating people with recurrent glioblastoma

Immunotherapy can be effective in treating people with recurrent glioblastoma

A bioengineered factory for T cells

A bioengineered factory for T cells

Tackling tumour scar tissue could be key to treating pancreatic cancer

Tackling tumour scar tissue could be key to treating pancreatic cancer

Improving the body's ability to fight cancer and intruders

Improving the body's ability to fight cancer and intruders

Immunotherapy appears better than chemotherapy for aggressive type of skin cancer

Immunotherapy appears better than chemotherapy for aggressive type of skin cancer

New ‘Trojan horse’ cancer treatment shows early promise in multiple tumour types

New ‘Trojan horse’ cancer treatment shows early promise in multiple tumour types

Ramucirumab with cisplatin and fluoropyrimidine does not increase survival in patients with metastatic gastric or gastro-oesophageal junctional adenocarcinoma

Ramucirumab with cisplatin and fluoropyrimidine does not increase survival in patients with metastatic gastric or...

Nullifying protein YTHDF1 enhances anti-tumour response

Nullifying protein YTHDF1 enhances anti-tumour response

Combination treatment, diabetes drug and immunotherapy, may help to fight breast cancer

Combination treatment, diabetes drug and immunotherapy, may help to fight breast cancer

More from ecancer